Communiqués Cabaletta Bio, Inc.

Actions

CABA

US12674W1099

Temps réel estimé Cboe BZX Autres places de cotation 18:56:48 16/07/2024			Varia. 5j.	Varia. 1 janv.
7,95 ^USD	+1,79 %		+1,74 %	-65,13 %

14/06	Mise à jour sectorielle : Les actions du secteur de la santé sont en baisse avant la cloche de vendredi	MT
14/06	Mise à jour sectorielle : Soins de santé	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum	02/07	GL
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum	02/07	AQ
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201	14/06	GL
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201	14/06	AQ
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference	29/05	GL
Cabaletta Bio : Corporate Presentation	15/05	PU
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update	15/05	GL
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	13/05	GL
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	13/05	AQ
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	21/03	GL
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	20/03	GL
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	20/03	AQ
Cabaletta Bio to Participate in Upcoming Investor Conferences in March	27/02	GL
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis	01/02	GL
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31/01	GL
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	08/01	GL
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	08/01	AQ
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference	02/01	GL
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference	28/11	GL
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update	09/11	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Cabaletta Bio, Inc.

Actions

CABA

US12674W1099

Communiqués

Filtres